T Cells - Tisagenlecleucel, cryopreserved - T - Kymriah Australia - English - Department of Health (Therapeutic Goods Administration)

t cells - tisagenlecleucel, cryopreserved - t - kymriah

novartis pharmaceuticals australia pty ltd - tisagenlecleucel -

T Cells - Tisagenlecleucel, cryopreserved - T - Kymriah Australia - English - Department of Health (Therapeutic Goods Administration)

t cells - tisagenlecleucel, cryopreserved - t - kymriah

novartis pharmaceuticals australia pty ltd - tisagenlecleucel -

QARZIBA dinutuximab beta 4.5 mg/mL concentrate for solution for infusion, 20 mg/4.5 mL vial Australia - English - Department of Health (Therapeutic Goods Administration)

qarziba dinutuximab beta 4.5 mg/ml concentrate for solution for infusion, 20 mg/4.5 ml vial

recordati rare diseases australia pty ltd - dinutuximab beta, quantity: 4.5 mg/ml - solution - excipient ingredients: polysorbate 20; hydrochloric acid; sucrose; water for injections; histidine - qarziba is indicated for the treatment of high-risk neuroblastoma in patients who have previously received induction chemotherapy and achieved at least a partial response.

Remsima 120mg solution for injection in pre-filled pen Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

remsima 120mg solution for injection in pre-filled pen

celltrion healthcare malaysia sdn. bhd. - infliximab -

Remsima 120mg solution for injection in pre-filled syringe Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

remsima 120mg solution for injection in pre-filled syringe

celltrion healthcare malaysia sdn. bhd. - infliximab -

Reopro Australia - English - Department of Health (Therapeutic Goods Administration)

reopro

eli lilly australia pty ltd - abciximab -

REOPRO SOLUTION Canada - English - Health Canada

reopro solution

janssen inc - abciximab - solution - 2mg - abciximab 2mg - miscellaneous therapeutic agents

REOPRO abciximab 10mg/5mL injection vial Australia - English - Department of Health (Therapeutic Goods Administration)

reopro abciximab 10mg/5ml injection vial

janssen-cilag pty ltd - abciximab -

Mabthera Australia - English - Department of Health (Therapeutic Goods Administration)

mabthera

roche products pty ltd - rituximab -

Mabthera New Zealand - English - Medsafe (Medicines Safety Authority)

mabthera

roche products (nz) ltd - rituximab 10 mg/ml (murine/human monoclonal antibody);  ;  ;   - concentrate for infusion - 10 mg/ml - active: rituximab 10 mg/ml (murine/human monoclonal antibody)       excipient: citric acid hydrochloric acid polysorbate 80 sodium chloride sodium citrate dihydrate water for injection - mabthera is indicated for the treatment of patients with: · cd20 positive, previously untreated low-grade or follicular, b-cell non-hodgkin's lymphoma in combination with chemotherapy. · cd20 positive, relapsed or chemoresistant low-grade or follicular, b-cell non-hodgkin's lymphoma. · cd20 positive diffuse large b-cell non-hodgkin's lymphoma in combination with chop (cyclophosphamide, doxorubicin, vincristine and prednisone) chemotherapy. mabthera is indicated for maintenance treatment of patients with cd20 positive, low grade or follicular, b-cell non-hodgkin's lymphoma.